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Identification of human plasma proteins as major clients for the extracellular
chaperone clusterin
Abstract
Clusterin (CLU) is an extracellular chaperone that is likely to play an important role in protein folding
quality control. This study identified three deposition disease-associated proteins as major plasma clients
for clusterin by studying CLU-client complexes formed in response to physiologically relevant stress
(shear stress, similar to 36 dynes/cm(2) at 37 degrees C). Analysis of plasma samples by size exclusion
chromatography indicated that (i) relative to control plasma, stressed plasma contained proportionally
more soluble protein species of high molecular weight, and (ii) high molecular weight species were far
more abundant when proteins purified by anti-CLU immunoaffinity chromatography from stressed plasma
were compared with those purified from control plasma. SDS-PAGE and Western blot analyses indicated
that a variety of proteins co-purified with CLU from both stressed and control plasma; however, several
proteins were uniquely present or much more abundant when plasma was stressed. These proteins were
identified by mass spectrometry as ceruloplasmin, fibrinogen, and albumin. Immunodot blot analysis of
size exclusion chromatography fractionated plasma suggested that CLU-client complexes generated in
situ are very large and may reach >= 4 x 10(7) Da. Lastly, sandwich enzyme-linked immunosorbent assay
detected complexes containing CLU and ceruloplasmin, fibrinogen, or albumin in stressed but not control
plasma. We have previously proposed that CLU-client complexes serve as vehicles to dispose of
damaged misfolded extracellular proteins in vivo via receptor-mediated endocytosis. A better
understanding of these mechanisms is likely to ultimately lead to the identification of new therapies for
extracellular protein deposition disorders.
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Clusterin (CLU) is an extracellular chaperone
that is likely to play an important role in
protein folding quality control. This study
identified three deposition disease-associated
proteins as major plasma clients for clusterin
by studying CLU-client complexes formed in
response to physiologically relevant stress
(shear stress ~ 36 dye/cm2 at 37o C). Analysis of
plasma
samples
by
size
exclusion
chromatography (SEC) indicated that (i)
relative to control plasma, stressed plasma
contained proportionally more soluble protein
species of high molecular weight (HMW), and
(ii) HMW species were far more abundant
when
proteins
purified by
anti-CLU
immunoaffinity chromatography from stressed
plasma were compared to those purified from
control plasma. SDS-PAGE and Western blot
analyses indicated that a variety of proteins copurified with CLU from both stressed and
control plasma, however, several proteins were
uniquely present or much more abundant
when plasma was stressed. These proteins were
identified
by
mass
spectrometry
as
ceruloplasmin (CERU), fibrinogen (FGN) and
albumin (HSA). Immunodot blot analysis of
SEC fractionated plasma suggested that CLUclient complexes generated in situ are very
large and may reach ≥ 4 x 107 Da. Lastly,
sandwich
ELISA
detected
complexes
containing CLU and CERU, FGN or HSA in
stressed but not control plasma. We have
previously
proposed
that
CLU-client
complexes serve as vehicles to dispose of
damaged misfolded extracellular proteins in
vivo via receptor-mediated endocytosis. A
better understanding of these mechanisms is
likely to ultimately lead to the identification of
new therapies for extracellular protein
deposition disorders.

Processes to attain and maintain native
protein conformations are vital for organismal
viability. Conditions such as thermal and
oxidative stress may cause proteins to partially
unfold and aggregate - a process thought to
underpin the pathology of many so-called protein
deposition diseases, including Alzheimer’s
disease, arthritis, type II diabetes, age-related
macular
degeneration
(ARMD)
and
atherosclerosis
(1-5).
While
intracellular
mechanisms to monitor and control the folding
state of proteins are well characterized,
corresponding extracellular mechanisms have yet
to be established. It has been proposed that
clusterin (CLU) is one of a small family of
abundant extracellular chaperones that form part
of a quality control system which acts to stabilize
misfolded, aggregating extracellular proteins and
mediate their clearance from the body via
receptor-mediated endocytosis and lysosomal
degradation (6-8).
CLU can stabilize proteins and prevent
their precipitation during exposure to a variety of
stresses in vitro (9-14). This action involves the
formation of soluble high molecular weight
(HMW) complexes incorporating both CLU and
the stressed client protein at an approximate mass
ratio of 1:2 (CLU:client); when generated in
vitro, these complexes have diameters of 50 - 100
nm (14). CLU is found associated with
extracellular protein deposits in many serious
diseases including drusen in ARMD (15), renal
immunoglobulin deposits in kidney disease (16),
prion deposits in Creutzfeldt-Jakob disease (17),
amyloid plaques in Alzheimer’s disease (18,19)
and also in atherosclerotic plaques (20). The
presence of CLU in these pathological deposits
suggests that it associates with unfolding proteins
in vivo. Pathological protein deposition may thus
result when the chaperone capacity of CLU and
other machinery acting to prevent the
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accumulation of protein aggregates is exceeded
by abnormally high levels of protein unfolding.
In addition to misfolded client proteins,
CLU also binds to many native ligands; the nature
of these latter interactions remain largely
uncharacterized, however, it is believed that CLU
has discrete binding sites for native ligands and
misfolded client proteins (12,21). Typically,
investigations of the chaperone activity of CLU
have been carried out using model proteins that
can be induced to unfold at experimentally
convenient rates. It was previously shown that
depletion of CLU from human plasma increased
the extent of plasma protein precipitation at both
60°C (11) and 37°C (22). However, the identity of
the major chaperone client proteins for CLU in
human plasma was previously unknown. The
identity of these client proteins may provide
important insights into mechanisms underlying
the development of extracellular protein
deposition diseases. In this study we exposed
human plasma to physiologically-relevant stress
(gentle rotation to produce shear stress ~36
dye/cm2 at 37°C for 10 days) and used
electrophoresis, Western blotting, and mass
spectrometry to identify proteins that co-purified
with CLU from stressed (but not control) plasma
by immunoaffinity chromatography. Immunodot
blot assays of fractions from size exclusion
chromatography (SEC), and sandwich ELISA,
were used to confirm that these putative
endogenous plasma client proteins formed soluble
HMW complexes with CLU in stressed human
plasma

1,020 x g for 30 min to pellet cells. The plasma
was collected and supplemented with CompleteTM
Protease Inhibitor Cocktail (Roche) and 0.1%
(w/v) sodium azide (Az). One 50 mL aliquot was
immediately filtered through a GF/C microfibre
glass filter (Whatman) and passed at 0.5 mL/min
over monoclonal anti-CLU immunoaffinity
columns (with an approximate total bed volume
of 20 mL), as previously described (25). The
columns were subsequently washed with several
column volumes of phosphate buffered saline
(PBS; 137 mM NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, 8 mM Na2 HPO4, pH 7.4) containing
0.1% (w/v) Az (i.e. PBS/Az) before the bound
protein was eluted using 2 M GdHCl in PBS, pH
7.4. A second 50 mL aliquot of plasma (from the
same batch) was "stressed" as follows: plasma
was held in a 100 mL Schott bottle in a Bioline
472 incubator shaker (Edwards Instrument Co.)
rotating at 200 rpm at 37°C for 10 days. This is
estimated to correspond to an approximate shear
stress of 36 dye/cm2 (24). Subsequently, this
sample was processed as above using the same
immunoaffinity procedure. In some cases, where
it was not possible to use freshly isolated plasma
as the control (i.e. in sandwich ELISA and
measurements of turbidity where absorbance
readings were required to be obtained
concurrently), control plasma (from the same
batch) was left static at room temperature for 10
days.
Plasma Protein Precipitation Assays Total plasma protein precipitation was assessed
by microprotein assay and by spectrophotometry.
For each plasma sample (control or stressed),
three 200 µL aliquots of plasma were filtered
using separate 0.45 µm Ultrafree®-MC
centrifugal filter devices (Millipore). The
precipitate collected on the membranes was
extensively washed with PBS. The membranes
were then covered with 200 µL of 6 M GdHCL in
PBS and incubated at 60°C with shaking
overnight. Parafilm “M” (Pechiney Plastic
Packaging) was used to seal the membrane cups
and ensure that no liquid volume was lost during
heating. The solutions were diluted 1:50 in PBS
before a BCA assay was performed (Smith et al.,
1985). In addition, control or stressed plasma was
diluted 1:2 in PBS/Az in a quartz cuvette and the
A360 nm measured using a WPA Biowave S2100

EXPERIMENTAL PROCEDURES
Materials - All buffer salts were obtained
from
Ajax
Chemical
Co.
Orthophenylenediamine, 2-β-mercaptoethanol, BCA
reagent, goat anti-FGN antiserum, goat antiCERU antiserum, rabbit anti-HSA antiserum,
control goat serum, control rabbit serum and
mouse anti-goat Ig-HRP were from SigmaAldrich. Sheep anti-rabbit Ig-HRP and control
mouse IgG1 were obtained from Millipore.
Purified mouse monoclonal anti-CLU IgG1 (G7)
was as described in (23).
Isolation of Plasma Proteins CoPurifying with CLU - Whole blood supplemented
with 20 µM sodium citrate was centrifuged at
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Diode Array Spectrophotometer (Biochrom).
Statistical significance was determined using oneway analysis of variance (ANOVA) and Tukey
HSD.
Size Exclusion Chromatography (SEC) SEC of 500 µL whole plasma or anti-CLU
immunoaffinity eluate was carried out using a
SuperoseTM 6 10/300 column (GE Healthcare)
equilibrated in PBS/Az at the recommended flow
rate of between 0.3-0.5 mL/min and the
absorbance at 280 nm (A280 nm) continuously
monitored using an ÄKTA FPLC system (GE
Healthcare). Mass standards were from a
commercial
HMW
calibration
kit
(GE
Healthcare). All buffers and samples were filtered
(0.45 µm) before use. For immunodot blot
analysis of whole plasma, 0.5 mL fractions were
collected.
SDS-PAGE and Identification of Proteins
by Mass Spectrometry - Proteins purified by antiCLU immunoaffinity chromatography from
plasma samples (40 mg total protein per lane)
were separated on 8-15% SDS-PAGE gels using
a HoeferTM SE 250/260 SDS-PAGE system (GE
Healthcare). Mass spectrometry was outsourced
commercially and performed by the Australian
Proteome Analysis Facility (APAF). Selected
Coomassie Blue stained bands were excised from
gels using a scalpel blade. Excised bands were
treated in-gel with PNGaseF followed by tryptic
digestion for 16 h. MALDI mass spectrometry
was performed with an Applied Biosystems 4800
Proteomics Analyzer. The spectra were acquired
in reflectron mode in the mass range 700 to 3500
Da. The instrument was then switched to MS/MS
(TOF/TOF) mode where peptides from the MS
scan were isolated and fragmented, then reaccelerated to measure their masses and
intensities. Spectra were then examined using the
database search program Mascot (Matrix Science
Ltd). High Mowse scores (> 69) in the peptide
database search indicated a likely match
(p < 0.05).
Western Blot and Immunodot Blot
Analyses - For Western blots, following SDSPAGE performed as described above (loading 10
µg total protein into each lane), gels were
subsequently equilibrated in transfer buffer
(26 mM TRIS, 192 mM glycine, 20% (v/v)
methanol, pH 8.3) and separated proteins
transferred to nitrocellulose membrane using a

Mini Trans-Blot Cell Western blotting apparatus
(Bio-Rad) at 100 V for 1 h at 4°C. The membrane
was subsequently blocked overnight at 4oC in 1%
(w/v) heat denatured casein (HDC) in PBS
(HDC/PBS). Primary and appropriate HRPconjugated secondary antibodies, diluted in
HDC/PBS
following
the
manufacturer's
instructions, were incubated in turn with the
membrane for 1 h at 37 °C. The membrane was
then washed in 0.1% (v/v) Triton X-100 in PBS
followed
by
PBS
alone.
Enhanced
chemiluminescence detection was performed
using Supersignal Western Pico substrate (Pierce
Biotechnology, Rockford, USA) following
the
manufacturer’s
protocols.
Amersham
HyperfilmTM ECL (GE Healthcare) was placed
over the membrane in a Kodak X-Omatic cassette
to detect chemiluminescence. Once exposed, the
film was removed from the cassette and
developed using Kodak Developer and Fixer.
Densitometry was performed using a GS 800
calibrated densitometer (Bio-Rad) and Quantity
One software (Bio-Rad). The average optical
density/mm2 of the bands was used to estimate
their relative quantities.
For immunodot blots, plasma (control or
stressed) was fractionated over a SuperoseTM 6
10/300 column as described above. Four
microliters of each 0.5 mL fraction was spotted
onto nitrocellulose membrane and allowed to dry
before a second 4 µL aliquot was applied. The
dried membranes were then blocked and
processed as described above for Western blot.
Sandwich ELISA - The wells of an
ELISA plate (Greiner Bio-one) were coated with
10 mg/mL purified G7 anti-CLU antibody (23) or
control mouse IgG1 antibody, then blocked with
1% (w/v) BSA in PBS (BSA/PBS) or HDC/PBS.
Control plasma (left static at room temperature)
or stressed plasma was next added to the wells.
Subsequently, primary antisera reactive with
either CERU, FGN or HSA diluted in the
blocking solution (following the manufacturer’s
instructions) were added to the appropriate wells.
Finally, an appropriate horseradish peroxidase
(HRP) conjugated secondary antibody diluted in
blocking solution (following the manufacturer’s
instructions) was added. All incubations were for
1 h at 37 ºC with shaking, and extensive washing
with PBS was performed between each step. The
final wash was performed using 0.1% (v/v)
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Triton-X 100 in PBS followed by PBS alone.
Ortho-phenylenediamine (2.5 mg/ml) and 0.03 %
(v/v) H2O2 in 50 mM citric acid, 100 mM
Na2 HPO4, pH 5 was then added to the wells of
the plate. The reaction was stopped using 1 M
HCL before the A490 nm was measured using a
SpectraMax Plus384 microplate reader (Molecular
Devices). Non-specific binding was assessed
using species–matched anti-sera of irrelevant
specificity and the appropriate secondary
antibody. The results presented are adjusted for
non-specific binding by calculating the
absorbance in wells coated with G7 relative to the
absorbance in wells coated with control mouse
IgG1 (of irrelevant specificity) that were treated
with the same plasma, primary and secondary
antibodies.
Statistical
significance
was
determined using Student’s t-test.

proportion of stressed plasma proteins migrated as
very large species. SEC profiles of proteins
purified
by
anti-CLU
immunoaffinity
chromatography from freshly isolated control
versus stressed plasma were very different
(Fig. 2B). The A280 peak eluting at the column
exclusion limit was approximately four times
greater for proteins immunoaffinity purified from
stressed plasma versus control plasma. Moreover,
the majority of species in the former sample were
larger than about 600 kDa whereas those in the
latter sample were predominately smaller in mass
(Fig. 2B).
Identification of major plasma clients for
clusterin. When equivalent amounts of total
protein purified by anti-CLU immunoaffinity
chromatography from control and stressed plasma
were analyzed side-by-side by reducing SDSPAGE, many bands were detected in both
samples (Fig. 3). A major band at about 36 kDa,
corresponding to the co-migrating α and β
subunits of CLU, was detected in both samples,
however, this was considerably more prominent
in the control sample (Fig. 3). In the sample
prepared from control plasma, other protein bands
detected probably include those representing
ApoA-I (~ 28 kDa) and IgG (light chain ~ 23 kDa
and heavy chain ~ 50 kDa), which are known to
co-purify with CLU from normal human plasma
(23,25), as well as other minor contaminants
which can be removed from CLU by subsequent
ion exchange chromatography (26). Additional
bands that were unique or more prominent in the
sample prepared from stressed plasma were also
detected (Fig. 3). Several of these bands
(indicated by empty arrowheads on Fig. 3) were
excised and subjected to mass spectrometry
analysis (multiple gels of various percentage
acrylamide were used to adequately resolve bands
for mass spectrometry, however a single
representative gel is shown). These analyses
identified ceruloplasmin (CERU), fibrinogen
(FGN; β chain) and human serum albumin (HSA)
as putative chaperone client proteins for CLU
(Table 1).
Western blot analysis was used to confirm
that CERU, FGN and HSA co-purified with CLU
from stressed plasma but not (or to a lesser extent)
from control plasma (Fig. 4). At most, only traces
of CERU and FGN were detected in the
corresponding protein fractions purified in the

RESULTS
Stress-induced protein precipitation.
After 10 days, compared to control plasma held at
room temperature, stressed plasma was visibly
more turbid. The turbidity of control plasma
remained unchanged over this period, however
after 10 days the turbidity of stressed plasma was
significantly greater than at day 0 and that of
control plasma at either time point (Fig. 1;
F (3,8) = 433, Tukey HSD, p < 0.0001 in all
cases). When performed as described, the
bicinchoninic (BCA) assay was unable to detect
protein in the filtrates of freshly obtained control
plasma but detected a mean ± standard error
(n = 3) of 8.47 ± 0.99 mg protein in the
corresponding filtrates from 200 µL aliquots of
stressed plasma.
Bias towards HMW species as detected by
SEC of stressed plasma and anti-CLU copurifying proteins. There were differences in the
SEC profiles of freshly isolated control and
stressed plasma samples (Fig. 2A). Most notably,
the respective areas underneath the traces of
absorbance at 280 nm (A280 nm) suggest that
there was less soluble protein in stressed plasma
compared to an equal volume of control plasma.
Although there appeared to be less soluble protein
in the stressed sample, the amount of protein
eluting at the exclusion limit of the column
(4 x 107 Da) was similar for both plasma samples
(Fig. 2A), indicating that overall a greater
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same way from control plasma (Fig. 4A and B).
There was measurable HSA in the fraction
prepared from control plasma, however, this was
reproducibly substantially less than in the sample
prepared from stressed plasma (Fig. 4C). A band
representing HSA was detected at about the
position expected for the intact molecule (69 kDa,
panel C), but the same was not true for CERU.
Intact CERU has a mass of 122 kDa, however it is
prone to autolysis in plasma to yield fragments of
67, 53 and 20 kDa (27) which corresponded to the
approximate position of the major bands detected
on the blot (Fig. 4A). Bands corresponding to the
α, β and γ chains of FGN (25 kDa, 56 kDa and 48
kDa, respectively) were detected in the lane
containing proteins from stressed plasma. In
plasma, FGN is highly susceptible to proteolysis
and is present in many fragmented and crosslinked forms (28,29). Therefore, FGN bands
detected between about 29-36 kDa are likely to
represent β and γ chain degradation products (Fig.
4B).
CLU forms HMW complexes with
chaperone client proteins in vitro (9,10,12,14). If
CLU-client protein complexes formed in situ in
plasma are also large, then relative to unstressed
control plasma, a greater proportion of CLU and
the client proteins would be detected as HMW
species in stressed plasma. This was examined
using SEC to fractionate both control and stressed
plasma on the basis of molecular size, and then
probing the fractions with specific antibodies. Fig.
5 shows immunodot blot results for SEC fractions
representing species corresponding to between
460 kDa and the exclusion limit of the column (≥
4 x 107 Da) in mass probed with specific
antibodies for CLU, CERU, FGN and HSA.
Strikingly, CLU and all three client proteins were
detected much more strongly in the HMW
fractions (≥ 4 x 107 Da) prepared from stressed
plasma compared to the corresponding fractions
of control plasma (Fig. 5). Most of the
corresponding fractions from control plasma
showed little reactivity with antibodies specific
for CLU, CERU, FGN and HSA. This is
consistent with the known mass of these
individual proteins (CLU 61 kDa, CERU 122
kDa, FGN 340 kDa and HSA 69 kDa) - the bulk
of these proteins would elute in later fractions not
represented in this figure unless they were present
as aggregates or complexes. The limited reactivity

detected for the client proteins in the control
plasma lanes probably represents low-level
associations of these proteins with other
unidentified plasma components or selfassociation (see Discussion).
The results thus far indicated a
preferential association of CERU, FGN and HSA
with CLU in stressed human plasma. If this
association was the result of the chaperone action
of CLU, then it would be expected that complexes
incorporating both CLU and one or more of these
three putative client proteins would be present in
stressed plasma but not in control plasma. This
was verified by sandwich ELISA. The wells of an
ELISA plate were coated with an anti-CLU
antibody (or an isotype-matched control antibody)
and subsequently incubated with control or
stressed plasma. Bound CERU, FGN or HSA
were then detected with specific antibodies. In
this assay, absorbance at 490 nm significantly
above that of the controls will only occur if
species containing both CLU and a putative client
protein are specifically bound to the anti-CLU
antibody on the wells. For all three putative client
proteins tested, significantly greater absorbance
was measured in wells incubated with stressed
plasma compared to those incubated with control
plasma (Fig. 6; CERU, FN and HSA t(4) = 9.06,
t(4) = 4.85, t(4) = 4.99, respectively; p ≤ 0.02 in
all cases). When irrelevant control antibodies
matched by isotype and species to the primary
detection antibody were used in the same assay,
there was no significant difference between wells
incubated with stressed or control plasma (control
antisera results, Fig. 6).
DISCUSSION
Exposure to physical and chemical
stresses, such as elevated temperature, shear
stress, oxidative stress and UV irradiation,
challenge all biological systems. One potential
impact of these stresses is damage to proteins,
inducing misfolding, loss of function and
aggregation. While much is known about
intracellular mechanisms that act to repair or
dispose of stress-damaged proteins, little is known
about corresponding extracellular mechanisms.
When
comparing
the
intracellular
and
extracellular environments, some stresses that can
contribute to protein unfolding are greater in the
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latter. This includes hydrodynamic shear stress
resulting from the hydraulic force of plasma being
pumped around the body (30,31); normal arterial
shear stress is between 10-70 dye/cm2 (32). The
extracellular environment is also more oxidizing
than the cytosol (33). In this study, we used a
constant temperature of 37°C and an estimated
shear stress (generated by orbital shaking) of
around 36 dye/cm2 (calculated using the formula
of (24)) to simulate physiologically-relevant
extracellular conditions. Relative to plasma left
stationary at room temperature, plasma stressed in
this way for 10 days showed increased turbidity
and protein precipitation (Fig. 1). This result
indicates that plasma proteins are prone to
unfolding and aggregation under conditions of
temperature and shear stress that are likely to
occur in vivo. If this is the case, then intuitively,
the human body must have systems in place to
control this problem.
SEC indicated that the level of soluble
protein remaining in stressed plasma was less
than in batch-matched control plasma, and that
proportionately more proteins were present as
HMW species in stressed plasma (Fig. 2). These
findings may be explained by the stress-induced
partial unfolding of plasma proteins, which
subsequently aggregate to form increasingly large
aggregates, some of which eventually become too
large to stay in solution and form insoluble
precipitate. Superimposed on this process, we
suggest that under these conditions CLU forms
large soluble complexes with probably many
different misfolded plasma client proteins. This
has the effect of ameliorating the extent of protein
precipitation measured. We have previously
shown that the immunoaffinity depletion of CLU
from human plasma significantly increased total
protein precipitation in this fluid when it was
subsequently incubated at either 60oC (11) or
37oC (22). Species ≥ 4 x 107 Da in stressed
plasma may be aggregates on their way towards
becoming insoluble or may be aggregates
stabilized by extracellular chaperones such as
CLU. CLU is itself physically very stable and
does not aggregate or precipitate even in response
to sustained heating at 60°C (9,12-14). Thus, the
apparent depletion of CLU from the pool of
soluble proteins in stressed plasma in the current
study (Fig. 3) probably results from its
incorporation into growing aggregates; under the

conditions tested, CLU is unable to maintain the
solubility of all plasma proteins. Supporting the
involvement of CLU in forming HMW
chaperone-client complexes, SEC of proteins
purified
by
anti-CLU
immunoaffinity
chromatography from stressed and control plasma
indicated that, relative to the latter, the former
was dominated by HMW protein species. If it had
been possible to elute proteins from the anti-CLU
columns using non-denaturing conditions (instead
of the 2M GdHCl used in this study), the
difference in mass profile for the two samples
might have been even greater. Our recent work
showed that when CLU-client protein complexes
were generated from purified proteins in vitro, the
mass ratio was, for each of three different client
proteins, approximately 1:2, respectively (14).
The complexes in the current study were purified
from stressed human plasma by immunoaffinity
chromatography, which (unavoidably) involved
eluting bound complexes with denaturing
conditions. The harsh elution conditions are likely
to have led to partial disruption of the complexes,
thus making measurements of stoichiometry
rather meaningless. For this reason we did not
measure the apparent stoichiometry of the
complexes in the current study.
SDS-PAGE analyses of proteins bound
from control plasma to anti-CLU columns were
consistent with our experience in routine
purifications of plasma CLU (26). The protein
bands detected (additional to CLU) are likely to
represent known CLU ligands such as
complement components (34), IgG (23) and ApoA1 (25). However, other bands were detected as
uniquely present (or more abundant) in samples
prepared from stressed plasma - these bands were
regarded as corresponding to putative endogenous
plasma client proteins for the chaperone action of
CLU. In this study, three bands were selected
from one-dimensional SDS-PAGE for further
analysis. It is expected that in the future, by
applying a protein separation technique with
greater resolution such as two-dimensional SDSPAGE, further putative client proteins will be
identified. Previous studies indicate that the
chaperone action of CLU is promiscuous (6,914,35), thus it is likely that CLU will interact with
most misfolding proteins, regardless of their
identity and that endogenous CLU-client
complexes will contain a heterogeneous mix of
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client proteins. However, using the approaches
described, identification of specific plasma
proteins as clients for CLU will depend on their
individual relative abundances and stabilities. In
the current study, mass spectrometric analysis of
the three bands resolved by one-dimensional
SDS-PAGE identified them as corresponding to
CERU, FGN and HSA (Fig. 3 and Table I).
Western blot analyses showed that these three
putative client proteins were preferentially
detected in protein fractions prepared by antiCLU immunoaffinity chromatography of stressed
plasma versus control plasma (Fig. 4). The small
amounts of the putative client proteins copurifying with CLU from control plasma (Fig. 4,
control (C) lanes) may be the result of low levels
of CLU-client complexes present in freshly
isolated plasma. However, low-level non-specific
binding of client proteins to the anti-CLU
immunoaffinity columns may also contribute in
this regard, particularly in the case of HAS, which
is known to bind to many surfaces.
Species much larger than expected for
monomeric CLU, CERU, FGN and HSA were
detected by immunodot blot analysis of SEC
fractionated samples of both control and stressed
plasma. CLU is well known to oligomerize in
solution to form a variety of HMW aggregates
(9,14) and also to associate with HDL particles in
plasma (25); this would account for the large
(460 kDa to > 737 kDa) CLU-containing species
detected in control plasma (Fig. 5A). In the case
of CERU, FGN and HSA, the large (>460 kDa)
species containing these proteins detected in
control plasma probably result from interactions
between them and other plasma proteins. Many
examples of such interactions are known, for
example lactoferrin (36), protein C (37),
myeloperoxidase (38) interact with CERU; at
least 11 proteins are known to interact with FGN
including
vitronectin
(39),
histidine-rich
glycoprotein (40) and apolipoprotein(a) (41); and
over 60 different proteins are believed to interact
with HSA (42). Also, self aggregation which has
been reported for both FGN (43) and HSA (44).
Corresponding analyses of stressed plasma
strongly detected CLU and each of the three client
proteins CERU, FGN and HSA in fractions
representing still larger species approaching (or
at) the exclusion limit of the SEC column (4 x 107
Da; Fig. 5). This observation is consistent with

CLU forming large HMW complexes with client
proteins in stressed plasma, as has been described
for purified proteins in buffered solutions
(9,10,12,14). Finally, using sandwich ELISA, we
were able to confirm that CLU-CERU, CLU-FGN
and CLU-HSA complexes were present in
stressed but not control plasma (Fig. 6).
Collectively, these results indicate that under
conditions of mild, physiologically-relevant
stress, CLU forms soluble chaperone-client
complexes in plasma containing one or more of
CERU, FGN and HSA.
The observation that CLU is found
associated with insoluble protein aggregates in all
protein deposition diseases in which this has been
examined (45) suggests that CLU (i) binds to
unfolding proteins in vivo, and (ii) becomes
incorporated into protein deposits when its
chaperone action is overwhelmed by an excess of
misfolded protein. All three CLU client proteins
identified in this study are involved in protein
deposition diseases. CERU, FGN and HSA are
found in ARMD deposits known as drusen
(15,46-49). Additionally, plasma concentrations
of CERU and FGN are higher in ARMD
compared to normal patients (50,51).
Colocalization of CLU with drusen proteins is very
common in ARMD (15), furthermore, in this
same disease, non-drusen FGN deposition is
implicated in the atrophy of the retinal pigment
epithelium and choroidal neovascularization
(52,53). The progression of both atrophic and
neovascular ARMD is supported by platelet
activation which results in secretion of growth
factors and monocyte chemoattractants. Platelet
activation is enhanced by unfolding of FGN (54)
and results in the release of CLU from the
platelets by degranulation (55). The effects of the
interaction between CLU and stressed FGN on
platelet activation are currently unknown - this
may have significance not only to ARMD, but
also to the many ischemic and atherosclerotic
vascular conditions where FGN deposition is
known to occur (5,56-58). As in ARMD,
fibrinogen deposition in such diseases is
associated with the recruitment and activation of
platelets and has been proposed as a mechanism
for vascular injury (59). Deposition of fibrinogen
(FGN) has been reported in breast cancer (60),
mesothelioma (61), colon cancer (62) and
lymphoma (63). Although the reasons for this are
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unknown, one potential implication of this
observation is that FGN deposition promotes
angiogenesis and cancer progression. FGN
deposits are also found in renal disease (64,65),
hereditary renal amyloidosis (66) and systemic
lupus erythematosus (67). In Type 1 (insulindependent) diabetes mellitus, extracellular
deposition of HSA is observed around dermal
capillaries (68), kidney (69,70), skeletal muscle
(71) and the thyroid gland (72).
Given the large number of diseases in
which extracellular protein deposition occurs (15,8), characterization of mechanisms that clear
damaged proteins in healthy individuals is likely
to shed light on how protein deposition
pathologies arise. In this study we have identified
three plasma client proteins that bind to CLU
during physiologically relevant stress. Their
deposition in numerous conditions suggests that
overwhelming or disruption of normal activities
that prevent their accumulation in healthy
individuals is important in the progression of
disease. The in vivo interaction of CLU with these

client proteins (and others) in vivo is likely to be
an important mechanism to prevent the
pathological deposition of misfolded extracellular
proteins. Significantly, it has been shown that
CLU knock-out mice develop progressive
glomerulopathy which is characterized by the
accumulation of insoluble protein deposits in the
kidneys (73). This directly implicates CLU in the
clearance of potentially pathological aggregating
proteins, although the precise mechanism
underlying this has yet to be described. It has
been proposed to occur via the receptor-mediated
endocytosis
and
subsequent
lysosomal
degradation of extracellular chaperone-client
protein complexes (6). Evidence is rapidly
accumulating that CLU and other abundant
extracellular chaperones are key elements in a
quality control system for extracellular protein
folding (6-14,21,22,35,45,74-79). This report is
an important step towards a fuller understanding
of the vital mechanisms involved in extracellular
protein folding quality control.
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The abbreviations used are: A280 nm, absorbance at 280 nm; A490 nm, absorbance at 490 nm; ARMD,
age-related macular degeneration; Az, sodium azide; BSA, bovine serum albumin; CERU, ceruloplasmin;
CLU, clusterin; FGN, fibrinogen; G7, monoclonal anti-CLU IgG1; HDC, heat denatured casein; HMW,
high molecular weight; HSA, human serum albumin; PBS, phosphate buffered saline; SEC, size exclusion
chromatography.
TABLE LEGENDS
Table 1. Identification of proteins by mass spectrometry. Proteins co-purifying with CLU from stressed
plasma (indicated by open arrows in Fig. 3) were analyzed by MALDI TOF/TOF. Spectra were examined
using the database search program Mascot (Matrix Science Ltd, London, UK). Mowse scores (> 69) in the
peptide database search indicated a likely match (p < 0.05).
FIGURE LEGENDS
Fig. 1. Turbidity of control and stressed plasma at day 0 and day 10. Plasma samples were diluted 1:2 in PBS on day
0 and day 10 and the A360 nm measured. The figure shows the average A360 nm (n = 3 ± standard error) for each
sample. * Denotes significantly increased turbidity relative to the three other sample types (Tukey HSD, p < 0.0001
in all cases). These results are representative of 3 independent experiments.

Fig. 2. SEC of (A) stressed or control plasma and (B) anti-CLU immunoaffinity purified proteins from stressed or
control plasma. Samples analyzed were: (A) whole plasma exposed to shear stress for 10 days or freshly isolated
control plasma, and (B) proteins purified by anti-CLU immunoaffinity chromatography from the plasma samples
described in (A). The positions of molecular weight markers are indicated by labelled arrows; the exclusion limit (Vo)
≥ 4 x 107 Da. The results shown are representative of 2 independent experiments.

Fig. 3. SDS-PAGE of proteins purified from stressed or control human plasma by anti-CLU immunoaffinity
chromatography. Proteins were separated using 12% SDS-PAGE under reducing conditions. The figure shows
molecular weight markers (left lane, masses indicated in kDa), and proteins immunoaffinity purified from freshly
isolated control plasma (labelled C) or stressed plasma (labelled S). Open arrows indicate bands that were selected
for mass spectrometry analysis. The solid black arrow indicates the position of CLU. The results shown are
representative of many independent experiments.
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Fig. 4. Western Blot analysis of proteins purified by anti-CLU immunoaffinity chromatography from control or
stressed human plasma. Proteins separated by SDS-PAGE (10 µg total protein loaded per lane) were transferred to
nitrocellulose membrane and probed with (A) anti-CERU, (B) anti-FGN or (C) anti-HSA antisera. Each panel shows
the position of molecular weight markers (left lanes, masses in kDa indicated), and proteins immunoaffinity purified
from freshly isolated control plasma (labelled C) or stressed plasma (labelled S). In (B), the position of the α, β and γ
subunits of FGN are indicated. The results shown are representative of 3 independent experiments.

Fig. 5. Immunodot blot analyses of SEC-fractionated control or stressed human plasma. Freshly isolated control
plasma (C) or stressed plasma (S) were fractionated using a SuperoseTM 6 column (V0 ≥ 4 x 107 Da). Aliquots from
each fraction were spotted onto nitrocellulose membrane which was then incubated with antibodies against (A) CLU,
(B) CERU, (C) FGN, or (D) HSA followed by the appropriate HRP-conjugated secondary antibody prior to
development by ECL. The approximate molecular weight of the SEC fractions is indicated at the top of the figure.
The results shown are representative of 3 independent experiment.
Fig. 6. Detection of CLU-client protein complexes in stressed plasma by sandwich ELISA. Results of sandwich
ELISA detecting CLU-client protein complexes containing (A) CERU, (B) FGN or (C) HSA in human plasma.
Results for "control antisera" were obtained using species-matched control antisera as the primary detection antibody
in each case. The results shown are the average A490 (n = 3, ± standard error) relative to the non-specific binding
generated in wells coated with mouse IgG1 control antibody. * Denotes increased A490 relative to wells incubated
with control plasma (stored static at 4°C; Student’s t-test, p ≤ 0.02). The results shown are representative of 3
independent experiments
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Table 1
BAND

MASS

IDENTITY

MOWSE
SCORE

COVERAGE

SIGNIFICANCE

1

17 kDa

CERU

175

35%

p < 0.05

2

43 kDa

FGN
(β chain)

157

54%

p < 0.05

3

67 kDa

HSA
and
CERU

398

54%

p < 0.05

97

34%

p < 0.05
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